JW Euvipharm, acquired by Korean top pharmaceutical company JW Group in 2019, aims to penetrate the Vietnamese and global pharmaceutical markets. With advanced GMP standards and a commitment to producing high-quality pharmaceuticals, JW Euvipharm strives to contribute to the health of the Vietnamese population and humanity as a whole. We operate by granting distribution rights to distributors and other pharmaceutical companies rather than directly bidding or selling to hospitals or pharmacies.